Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00106132 · ClinicalTrials.gov registry record · Phase 3

Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage

A Phase 3 study of Macular Edema and Retinal Vein Occlusion, sponsored by National Eye Institute (NEI).

Completed
Registry status
Phase 3
Development phase
1,260
Enrollment target
1
Study location

NCT00106132: Completed Phase 3 study of Macular Edema and Retinal Vein Occlusion, sponsored by National Eye Institute (NEI).

NCT00106132 is a Phase 3 study of Macular Edema and Retinal Vein Occlusion that has completed, run by National Eye Institute (NEI). The registered enrollment target is 1,260 participants, above the 90-participant average among 14 other Macular Edema trials with a reported enrollment target (1300% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00106132, a Phase 3 study of Macular Edema and Retinal Vein Occlusion, has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
Phase 3
Development phase
1,260 participants
Enrollment target
1
Study location

Study Summary

This study will compare the safety and effectiveness of two treatments-injections of triamcinolone acetonide into the eye vs. standard laser therapy-for macular edema (swelling in the center of the retina) that is caused by blockage in a retinal blood vessel. Edema caused by blockage in a large vessel is called central retinal vein occlusion (CRVO). Edema caused by blockage in a smaller vein is called branch retinal vein occlusion (BRVO). Triamcinolone acetonide is a steroid drug that reduces swelling; the Food and Drug Administration has approved it for injection into joints and muscles to treat inflammatory conditions. Patients 18 years of age and older with macular edema due to CRVO or BRVO of between 3 and 18 months' duration may be eligible for this study. Candidates are screened with a medical history, blood pressure measurement, and urine pregnancy test for women who can become pregnant. Screening also includes the following procedures: * Eye examination to assess visual acuity and eye pressure, and to examine the cornea, lens, and retina. The pupils are dilated with drops for this examination. * Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. * Optical coherence tomography to measure retinal thickness. The eye is examined with a machine that produces cross-sectional pictures of the retina. The patient is seated in front of a machine and looks at a pattern of flashing and rotating red and green lights, first with one eye and then with the other. * Fundus photography to help evaluate the status of the retina and changes that may occur in the future. Photographs of the retina are taken using a camera that flashes a bright light into the eye. Participants

Interventions

  • DRUG Triamcinolone Acetonide

Study Locations (1)

Maryland

  • National Eye Institute (NEI) - Bethesda

Trial Details

FieldValue
Enrollment Target 1,260 participants
Start Date 2005-03
Est. Completion 2005-11
Phase Phase 3
National Eye Institute (NEI)

221 total trials

What the finished NCT00106132 record still lists

NCT00106132 is an interventional study that assigns participants to a tested intervention. Its 1,260 participants enrollment target places it among the larger protocols in the corpus, above the 90-participant average among 14 other Macular Edema trials with a reported enrollment target (1300% higher).

The record links to 3 conditions, with Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Triamcinolone Acetonide is the first listed.

NCT00106132 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00106132 about?

NCT00106132 is a clinical study titled "Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage". This study will compare the safety and effectiveness of two treatments-injections of triamcinolone acetonide into the eye vs. standard laser therapy-for macular edema (swelling in the center of the retina) that is caused by blockage in a retinal blood vessel. Edema caused by blockage in a large vess...

What is the current status of trial NCT00106132?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,260 participants. The study started on 2005-03. Estimated completion is 2005-11.

What conditions does trial NCT00106132 study?

This clinical trial studies the following conditions: Macular Edema, Retinal Vein Occlusion, Macular Edema, Cystoid.

What interventions are being tested in trial NCT00106132?

The interventions under investigation include: Triamcinolone Acetonide (DRUG).

Who is sponsoring clinical trial NCT00106132?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00106132 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Macular Edema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00106132's enrollment target sits among peer trials

1,260 1st of 14 higher than 14 of 14 other Macular Edema trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06712316 · 1,260 participants · Phase 2

    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • NCT06812273 · 1,260 participants · NA

    Mediators and Moderators of Auditory Training

  • NCT06931340 · 1,260 participants · Phase 3

    Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • NCT06119581 · 1,264 participants · Phase 3

    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00106132, the US trial registry maintained by the National Library of Medicine. NCT00106132 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.